These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18261372)

  • 1. Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan.
    Su Y; Hu P; Lee SH; Sinko PJ
    J Pharm Pharm Sci; 2007; 10(4):519-36. PubMed ID: 18261372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
    Zhang S; Wang X; Sagawa K; Morris ME
    Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.
    Yamasaki T; Fujinaga M; Kawamura K; Hatori A; Yui J; Nengaki N; Ogawa M; Yoshida Y; Wakizaka H; Yanamoto K; Fukumura T; Zhang MR
    Nucl Med Biol; 2011 Jul; 38(5):707-14. PubMed ID: 21718946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
    Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
    Drug Metab Dispos; 2007 Jul; 35(7):1142-8. PubMed ID: 17446265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
    Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
    J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter.
    Sawangrat K; Yamashita S; Tanaka A; Morishita M; Kusamori K; Katsumi H; Sakane T; Yamamoto A
    J Pharm Sci; 2019 Mar; 108(3):1315-1325. PubMed ID: 30389568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
    Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
    Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats.
    Matsuda Y; Konno Y; Hashimoto T; Nagai M; Taguchi T; Satsukawa M; Yamashita S
    Drug Metab Dispos; 2013 Aug; 41(8):1514-21. PubMed ID: 23686319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A; Amidon GL
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of novobiocin as a selective inhibitor of intestinal breast cancer resistance protein (Bcrp) in rats.
    Suzuki K; Taniyama K; Aoyama T; Watanabe Y
    Xenobiotica; 2020 Sep; 50(9):1121-1127. PubMed ID: 31868552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antisense oligonucleotide reverses topotecan-resistant ovarian cancer cells].
    Jia P; Wu SB; Xu Q; Wu MF; Gao QL; Liao GN; Lu YP; Ma D
    Ai Zheng; 2003 Dec; 22(12):1296-300. PubMed ID: 14693055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated system exposures of baicalin after combinatory oral administration of rhein and baicalin: Mainly related to breast cancer resistance protein (ABCG2), not UDP-glucuronosyltransferases.
    Zhang Y; Zhang M; Hu G; Zhang Z; Song R
    J Ethnopharmacol; 2020 Mar; 250():112528. PubMed ID: 31884038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone.
    Yang CH; Chen YC; Kuo ML
    Anticancer Res; 2003; 23(3B):2519-23. PubMed ID: 12894535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.
    Zhang D; Frost CE; He K; Rodrigues AD; Wang X; Wang L; Goosen TC; Humphreys WG
    Drug Metab Dispos; 2013 Apr; 41(4):906-15. PubMed ID: 23386703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP).
    Gupta A; Unadkat JD; Mao Q
    J Pharm Sci; 2007 Dec; 96(12):3226-35. PubMed ID: 17518356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model.
    Dallas S; Salphati L; Gomez-Zepeda D; Wanek T; Chen L; Chu X; Kunta J; Mezler M; Menet MC; Chasseigneaux S; Declèves X; Langer O; Pierre E; DiLoreto K; Hoft C; Laplanche L; Pang J; Pereira T; Andonian C; Simic D; Rode A; Yabut J; Zhang X; Scheer N
    Mol Pharmacol; 2016 May; 89(5):492-504. PubMed ID: 26893303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions.
    Chu J; Panfen E; Wang L; Marino A; Chen XQ; Fancher RM; Landage R; Patil O; Desai SD; Shah D; Xue Y; Sinz M; Shen H
    Pharm Res; 2023 Nov; 40(11):2567-2584. PubMed ID: 37523014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.